Event-Driven Stocks

Cidara Therapeutics, Inc.

CDTX

Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 4 warning● 2 severedetails ↓

Financials

SEC XBRL · annual
 FY24FY23FY22FY21FY20FY19
Revenue$1.3M$1.5M$0———
Operating income−$176.1M−$27.1M−$18.5M−$42.3M−$71.8M−$41.7M
Net income−$169.8M−$22.9M−$18.5M−$42.5M−$72.1M−$41.1M
Total assets$214.8M$67.0M$55.1M$75.3M$60.4M$69.0M
Total liabilities$51.5M$75.2M$58.8M$53.8M$49.7M$31.1M
Equity$163.3M−$8.2M−$14.4M$13.1M$10.7M$37.8M
EPS (diluted)$-26.75$-5.25$-0.27$-0.81$-1.80$-1.37
Shares out.91.2M89.0M68.2M48.0M40.5M27.8M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2024
Operating margin
−13811.9%
Net margin
−13319.8%
Return on equity
−104.0%
Return on assets
−79.1%
Return on capital (ROCE)
−106.6%
Liabilities / assets
24.0%
Debt / equity
0.32×
Book value / share
$1.79
Revenue growth (YoY)
−13.1%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2024
Altman Z″ (distress)
-6.53distress
Accruals / assets
3.1%clean
Piotroski F-Score
2/9weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
35
/ 100
Profitability 0Growth 0Catalyst 67Earnings quality 33Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 2 severe● 4 warning● 2 good
  • Altman Z″ in the distress zone
  • Filed a late-filing notice (Form NT) — missed an SEC deadline
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Revenue declined year-over-year
  • Negative operating cash flow
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Risk flags

late SEC filings

A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
Dec 31, 20251.9M2.2-6.8%
Dec 15, 20252.0M1.9-4.5%
Nov 28, 20252.1M1.0-35.9%
Nov 14, 20253.3M1.5+3.0%
Oct 31, 20253.2M3.7+7.4%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (3)